Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S65487 + azacitidine
- Development stage
- Phase 2
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
S65487 is an investigational small molecule that acts as a selective inhibitor of the Bcl2 protein, which plays a key role in regulating apoptosis (programmed cell death) in cancer cells. By inhibiting Bcl2, S65487 promotes apoptosis in malignant cells. Azacitidine is a pyrimidine nucleoside analogue and hypomethylating agent used for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and other hematologic malignancies. It works primarily by inhibiting DNA methyltransferase, leading to hypomethylation of DNA and reactivation of tumor suppressor genes, as well as direct cytotoxicity through incorporation into RNA and DNA. The combination of S65487 with azacitidine is being studied for its potential synergistic effects in treating adults with untreated AML who are not suitable for intensive chemotherapy[2][4][5][6].
- Brand names
- MylosarLadakamycin
- Other names
- 5-Azacytidine5-AZC
02
Targets
BCL-2 (BCL-2 family)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on S65487 + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S65487 + azacitidine.